Cancer diagnostics firm Exact Sciences' Q4 revenue rises

Reuters02-14

Cancer diagnostics firm Exact Sciences' Q4 revenue rises

Overview

Cancer screening firm's Q4 revenue rose 23%, beating analyst expectations
Adjusted EBITDA for Q4 was $63 mln, affected by $75 mln R&D expense

Outlook

Exact Sciences anticipates momentum from core products and portfolio expansion
Exact Sciences' merger with Abbott expected to close in Q2 2026

Result Drivers

SCREENING REVENUE - Screening revenue increased 26% to $695 mln, driven by Cologuard tests and PreventionGenetics
PRECISION ONCOLOGY - Precision Oncology revenue rose 14% to $183 mln, supported by Oncotype DX and therapy selection tests

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Beat	$878.38 mln	$860.90 mln (21 Analysts)
Q4 Net Income		-$85.96 mln
Q4 Basic EPS		-$0.45
Q4 Income From Operations		-$82.6 mln
Q4 Pretax Profit		-$85.08 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 20 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Exact Sciences Corp is $105.00, about 1.7% above its February 12 closing price of $103.23
The stock recently traded at 315 times the next 12-month earnings vs. a P/E of 270 three months ago

Press Release: ID:nBw9FlpYDa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611019382?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-14 05:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611019382","market":"fut","top_or_hot":-1,"title":"Cancer diagnostics firm Exact Sciences' Q4 revenue rises","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer diagnostics firm Exact Sciences' Q4 revenue rises</title></head><body><p><span>Overview</span></p><ul><li><p>Cancer screening firm's Q4 revenue rose 23%, beating analyst expectations</p></li><li><p>Adjusted EBITDA for Q4 was $63 mln, affected by $75 mln R&amp;D expense</p></li></ul><p><span>Outlook</span></p><ul><li><p>Exact Sciences anticipates momentum from core products and portfolio expansion</p></li><li><p>Exact Sciences' merger with Abbott expected to close in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SCREENING REVENUE - Screening revenue increased 26% to $695 mln, driven by Cologuard tests and PreventionGenetics</p></li><li><p>PRECISION ONCOLOGY - Precision Oncology revenue rose 14% to $183 mln, supported by Oncotype DX and therapy selection tests</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$878.38 mln</p></td><td><p>$860.90 mln (21 Analysts)</p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$85.96 mln</p></td><td></td></tr><tr><td><p>Q4 Basic EPS</p></td><td></td><td><p>-$0.45</p></td><td></td></tr><tr><td><p>Q4 Income From Operations</p></td><td></td><td><p>-$82.6 mln</p></td><td></td></tr><tr><td><p>Q4 Pretax Profit</p></td><td></td><td><p>-$85.08 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 20 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Exact Sciences Corp is $105.00, about 1.7% above its February 12 closing price of $103.23</p></li><li><p>The stock recently traded at 315 times the next 12-month earnings vs. a P/E of 270 three months ago</p></li></ul><p>Press Release: <span>ID:nBw9FlpYDa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cancer diagnostics firm Exact Sciences' Q4 revenue rises</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCancer diagnostics firm Exact Sciences' Q4 revenue rises\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-14 05:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer diagnostics firm Exact Sciences' Q4 revenue rises</title></head><body><p><span>Overview</span></p><ul><li><p>Cancer screening firm's Q4 revenue rose 23%, beating analyst expectations</p></li><li><p>Adjusted EBITDA for Q4 was $63 mln, affected by $75 mln R&amp;D expense</p></li></ul><p><span>Outlook</span></p><ul><li><p>Exact Sciences anticipates momentum from core products and portfolio expansion</p></li><li><p>Exact Sciences' merger with Abbott expected to close in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SCREENING REVENUE - Screening revenue increased 26% to $695 mln, driven by Cologuard tests and PreventionGenetics</p></li><li><p>PRECISION ONCOLOGY - Precision Oncology revenue rose 14% to $183 mln, supported by Oncotype DX and therapy selection tests</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$878.38 mln</p></td><td><p>$860.90 mln (21 Analysts)</p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$85.96 mln</p></td><td></td></tr><tr><td><p>Q4 Basic EPS</p></td><td></td><td><p>-$0.45</p></td><td></td></tr><tr><td><p>Q4 Income From Operations</p></td><td></td><td><p>-$82.6 mln</p></td><td></td></tr><tr><td><p>Q4 Pretax Profit</p></td><td></td><td><p>-$85.08 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 20 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Exact Sciences Corp is $105.00, about 1.7% above its February 12 closing price of $103.23</p></li><li><p>The stock recently traded at 315 times the next 12-month earnings vs. a P/E of 270 three months ago</p></li></ul><p>Press Release: <span>ID:nBw9FlpYDa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861558580.USD","symbol_name":"日兴方舟颠覆性创新基金B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nL1N3Z9175:1","article_id":"2611019382","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611019382","pubTimestamp":1771017296,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cancer diagnostics firm Exact Sciences' Q4 revenue risesOverviewCancer screening firm's Q4 revenue rose 23%, beating analyst expectationsAdjusted EBITDA for Q4 was $63 mln, affected by $75 mln R&D exp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4548":"巴美列捷福持仓","EXAS":"精密科学","BK4139":"生物科技","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD"},"translate_title":"癌症诊断公司Exact Sciences第四季度收入增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXAS":0.9},"content_text":"Cancer diagnostics firm Exact Sciences' Q4 revenue risesOverviewCancer screening firm's Q4 revenue rose 23%, beating analyst expectationsAdjusted EBITDA for Q4 was $63 mln, affected by $75 mln R&D expenseOutlookExact Sciences anticipates momentum from core products and portfolio expansionExact Sciences' merger with Abbott expected to close in Q2 2026Result DriversSCREENING REVENUE - Screening revenue increased 26% to $695 mln, driven by Cologuard tests and PreventionGeneticsPRECISION ONCOLOGY - Precision Oncology revenue rose 14% to $183 mln, supported by Oncotype DX and therapy selection testsKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueBeat$878.38 mln$860.90 mln (21 Analysts)Q4 Net Income-$85.96 mlnQ4 Basic EPS-$0.45Q4 Income From Operations-$82.6 mlnQ4 Pretax Profit-$85.08 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 20 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for Exact Sciences Corp is $105.00, about 1.7% above its February 12 closing price of $103.23The stock recently traded at 315 times the next 12-month earnings vs. a P/E of 270 three months agoPress Release: ID:nBw9FlpYDaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611019382","isCrawlerRequest":true}